Evidence map›Paper›PMID 30026491›Full record

ArticleNature communications2018

Designing a norepinephrine optical tracer for imaging individual noradrenergic synapses and their activity in vivo.

Matthew Dunn, Adam Henke, Samuel Clark, Yekaterina Kovalyova, Kimberly A Kempadoo, Richard J Karpowicz, Eric R Kandel, David Sulzer, Dalibor Sames

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 67 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. An ActivatableChemistryOpen · 2022
    Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Matthew DunnDepartment of Chemistry, Columbia University, New York, NY, 10027, USA.
Adam HenkeDepartment of Chemistry, Columbia University, New York, NY, 10027, USA.
Samuel ClarkDepartment of Neurology, Columbia University, New York, NY, 10032, USA.ORCID http://orcid.org/0000-0001-9494-4632
Yekaterina KovalyovaDepartment of Chemistry, Columbia University, New York, NY, 10027, USA.ORCID http://orcid.org/0000-0002-7815-7302
Kimberly A KempadooDepartment of Neuroscience, Columbia University, New York, NY, 10032, USA.
Richard J KarpowiczDepartment of Chemistry, Columbia University, New York, NY, 10027, USA.
Eric R KandelDepartment of Psychiatry, Columbia University, New York, NY, 10032, USA.
David SulzerDepartment of Neurology, Columbia University, New York, NY, 10032, USA. ds43@columbia.edu.
Dalibor SamesDepartment of Chemistry, Columbia University, New York, NY, 10027, USA. ds584@columbia.edu.
Columbia University · USAllen Institute for Brain Science · US

Funding

The Presynaptic Vesicle Cycle for the Slow Acting Neurotransmitter SecretionP01DA010154 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI EDWARDS, ROBERT H, KREITZER, ANATOL · 1995 to 2016
$14.7M
The Dopamine Synapse and Associative LearningR01DA007418 · NIDA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David Sulzer · 1999 to 2026
$9.4M
Development of Fluorescent False NeurotransmittersR01MH108186 · NIMH · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI SAMES, DALIBOR, SULZER, DAVID · 2015 to 2024
$5.8M
Optical imaging of dopamine kinetics in prefrontal cortex of normal and schizophrenia model miceF31MH109293 · NIMH · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CLARK, SAMUEL · 2016 to 2018
$132k
NIDA NIH HHS P01 DA010154NIDA NIH HHS R01 DA007418NIMH NIH HHS F31 MH109293NIMH NIH HHS R01 MH108186U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH108186
6 · The paper itself

Abstract

Norepinephrine is a monoamine neurotransmitter with a wide repertoire of physiological roles in the peripheral and central nervous systems. There are, however, no experimental means to study functional properties of individual noradrenergic synapses in the brain. Development of new approaches for imaging synaptic neurotransmission is of fundamental importance to study specific synaptic changes that occur during learning, behavior, and pathological processes. Here, we introduce fluorescent false neurotransmitter 270 (FFN270), a fluorescent tracer of norepinephrine. As a fluorescent substrate of the norepinephrine and vesicular monoamine transporters, FFN270 labels noradrenergic neurons and their synaptic vesicles, and enables imaging synaptic vesicle content release from specific axonal sites in living rodents. Combining FFN270 imaging and optogenetic stimulation, we find heterogeneous release properties of noradrenergic synapses in the somatosensory cortex, including low and high releasing populations. Through systemic amphetamine administration, we observe rapid release of cortical noradrenergic vesicular content, providing insight into the drug's effect.

Indexed as

Adrenergic NeuronsAnimalsAnimals, Genetically ModifiedBrainDrug DesignFluorescent DyesGreen Fluorescent ProteinsHEK293 CellsHumansMice, Inbred C57BLMicroscopy, FluorescenceMolecular ImagingNorepinephrineSynapsesSynaptic VesiclesFluorescent DyesGreen Fluorescent ProteinsNorepinephrine

Identifiers

PMID30026491
PMCPMC6053466
OpenAlexW2882976117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.